Home
overview
A two day intensive conference which will help you:

· KEEP up with the latest developments in the cardiovascular and hypertension market

· IMPROVE your knowledge of the industry

· ESTABLISH valuable industry contacts

· LEARN from the leading experts in the cardiovascular and hypertension field

· EVALUATE current treatments and opportunities in cardiovascular and hypertension

Conference programme

9:00 Registration and Coffee

9:30 Chairman's Opening Remarks

Dr T R Auton

Dr T R Auton, Head of Biomedical Statistics, Protherics

9:40 ANTIHYPERTENSIVE MARKET DYNAMICS

Helen Smith

Helen Smith, Director, Cardiovascular & Diabetes Services, Datamonitor

  • Antihypertensive drugs: size, growth and market drivers
  • ACE vs AIIRBs: the battle for sales supremacy
  • Niche hypertensive populations: diagnosis, treatment rates and combination therapy
  • Benefits beyond blood pressure lowering
  • What’s in the pipeline?
  • Forecasts for the market to 2008
  • 10:20 HYPERTENSION: MORE THAN JUST NUMBERS

    Dr Milton Pressler

    Dr Milton Pressler, Executive Director, Cardiovascular Clinical Development, Pfizer

  • The scale of the problem: the global burden of hypertension
  • When is BP too high? How low to treat
  • Is arrogance or ignorance the problem with achieving control?
  • The importance of hypertension therapies - outcomes
  • Complications of hypertension - end-organ disease
  • Issues for further development in hypertension
  • 11:00 Morning Coffee

    11:20 SPECIAL PATIENT POPULATIONS IN HYPERTENSION TRIALS

    Dr Alan Davies / Peter Djuric

    Dr Alan Davies / Peter Djuric, Therapeutic Director, Internal Medicine & Paediatrics / Director, Cardiovascular Clinical Research, Kendle International

  • Hypertension studies in the elderly
  • Paediatric populations
  • Renal impairment
  • Hepatic impairment
  • Mixed patient populations - eg: diabetics with arthritis and hypertension
  • Study design considerations, including duration of study, dropped dose design

    Compliance

  • 12:00 NEW TECHNIQUES TO ASSESS SURROGATE MARKERS

    Dr Philip Chowienczyk

    Dr Philip Chowienczyk, Senior Lecturer in Clinical Pharmacology, St. Thomas' Hospital, Kings College London

  • Endothelial function and vascular stiffness as targets for therapy
  • Limitations of current methods
  • New methods
  • 12:40 Lunch

    14:00 ENDOTHELIN RECEPTOR ANTAGONISTS IN HYPERTENSION

    Dr Tommy Brock

    Dr Tommy Brock, Vice President, Pharmacology & Preclinical Development, Texas Biotechnology

  • Pathophysiological role of endothelin in hypertension · Vasoconstriction · Vascular remodelling
  • Development of selective ETA receptor antagonists
  • Clinical efficacy of endothelin antagonists
  • Opportunities for new drugs in an already crowded market
  • 14:40 AN ANGIOTENSIN IMMUNOTHERAPEUTIC VACCINE FOR THE TREATMENT OF HYPERTENSION

    Dr T R Auton

    Dr T R Auton, Head of Biomedical Statistics, Protherics

  • Advantages of an immunotherapeutic approach to hypertension
  • Mechanism of action
  • Summary of animal pharmacology results
  • Summary of early phase clinical data
  • 15:20 Afternoon Tea

    15:40 PULMONARY ARTERIAL HYPERTENSION (PAH)

    David Crockford

    David Crockford, Vice President, Corporate Development & Scientific Affairs, Profile Therapeutics

  • PAH – the disease
  • The disease target
  • Current therapeutic modalities
  • Targeted inhalation therapy
  • 16:20 LEGAL ISSUES

    Archana Daniels

    Archana Daniels, Solicitor, Bristows

  • Regulatory guidelines for anti-hypertensives
  • Obtaining regulatory approval
  • Safety and clinical efficacy
  • Patent expiry/data exclusivity issues-keeping generics at bay
  • Improving the regulatory process
  • 17:00 Chairman's Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr J D Fitzgerald

    Dr J D Fitzgerald, Consultant, Materia Medica

    9:10 VASCULAR PROTECTANTS

    Dr Mitchell Glass

    Dr Mitchell Glass, Senior Vice President, Strategic Drug Development & Chief Medical Officer, AtheroGenics

  • Review of biology and chemistry of vascular protectants
  • Review of top line animal pharmacology
  • Top line clinical trial results that validate vascular (v-) protectants as a new target for drug development
  • Next steps
  • 10:20 THE DISCOVERY OF ACE INHIBITORS

    Dr J D Fitzgerald

    Dr J D Fitzgerald, Consultant, Materia Medica

  • Why did exploitation take so long?
  • Is target validation any better today?
  • Relevance to decision taking in research
  • Lessons of possible relevance
  • 11:00 Morning Coffee

    11:20 HYPERLIPIDEMIA

    Dr Nicola Maidwell

    Dr Nicola Maidwell, Analyst, Decision Resources I

  • Hyperlipidemia Market - Current Status
  • Medical Practice
  • Clinical Unmet Needs
  • Statin Challengers
  • Winners in 2010
  • 12:00 TRANSLATION OF GENOMIC FINDINGS INTO CARDIOVASCULAR THERAPEUTICS

    Dr Michael Shi

    Dr Michael Shi, Senior Director of Target Discovery & Development, Sequenom

  • Single-nucleotide polymorphism (SNP) and common genetic diseases
  • Genome wide SNP association studies for complex disease gene discovery
  • Target validation using human genetics
  • Novel gene targets for cardiovascular therapeutics
  • Developmental strategies for gene targets
  • 12:40 Lunch

    14:00 GENE TRANSFER TO INCREASE MYOCARDIAL CONTRACTILITY IN HEART FAILURE

    Dr Kirk Hammond

    Dr Kirk Hammond, Professor of Medicine / Scientific Founder, University of California San Diego/Collateral Therapeutics

  • Rationale
  • Adenylate cyclase gene transfer
  • FGF.4 Gene transfer in heart failure
  • Clinical trials of gene transfer
  • 14:40 THROMBOSIS

    Sanjay Kakkar

    Sanjay Kakkar, Chief Executive Officer, Trigen

  • Spectrum of disease and need for chronic therapy
  • Uses of currently marketed agents and their limitations
  • Recent developments giving rise to new classes of agents in development
  • Direct Thrombin Inhibitors – finally delivering on a long-held promise?
  • 15:20 Afternoon Tea

    15:40 PAEDIATRIC CLINICAL STUDIES FOR LABELING AND EXCLUSIVITY

    Dr Margo Mazur Schleman

    Dr Margo Mazur Schleman, Executive Director of Clinical Research, AstraZeneca

  • Regulatory issues for consideration-US
  • Regulatory Issues for consideration-Europe
  • Trial design issues
  • Ethical considerations
  • Consent issues
  • Dosing for children; results from trials
  • 16:20 DEFENDING AGAINST COMPETITION

    Tom Blackett

    Tom Blackett, Group Deputy Chairman, Interbrand

  • Using branding to defend against generic competition
  • Corporate branding
  • Using branding to your advantage
  • Portfolio management
  • 17:00 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    Strategic Product Planning
    Workshop

    Strategic Product Planning

    The Hatton, at etc. venues
    31st May 2002
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.